The short version
The selected early human study investigated long-acting CJC-1295 and hormone levels, rather than recovery from an injury.
An investigational profile is not an endorsement or a finding of safety.
Names you may see
Compound names, research identifiers, brand names and informal shorthand serve different purposes.
- CJC-1295 / CJC1295
- Research name and spelling variant · The long-acting CJC study summarized here concerns the DAC-containing compound.
- CJC-1295 with DAC
- Variant clarification · Identifies the long-acting form discussed in this evidence profile.
- CJC without DAC / Mod GRF 1-29
- Related label—different variant · Keep separate from the DAC-containing compound; evidence is not interchangeable.
Similar names do not establish identical ingredients, molecular variants, product quality or interchangeable preparations. A blend nickname may describe different formulas.
Things worth checking
Does the evidence match the preparation being discussed?
Check the exact product or substance, route, population and outcome. Ask which findings apply to your question, rather than assuming every product with the same ingredient name is equivalent.
Question to discuss · FDA · Compounding safety information ↗
Questions to bring to a clinician or pharmacist
- Which findings apply to my goal and medical history?
- Could my medicines, supplements, or other compounds change the assessment?
- What monitoring, if any, would inform a decision—and what symptoms would need evaluation?
Monitoring is individual. Normal bloodwork does not establish that a compound or preparation is safe.
Clinical research
Selected human hormone research is summarized below.
Early human hormone studies (2006)
Summary based on: Published abstract
- Study design
- Two randomized, double-blind, placebo-controlled studies lasting 28 and 49 days.
- Who was studied
- Healthy adults aged 21–61 years.
- Route and preparation
- Subcutaneous injection of the studied long-acting CJC-1295.
- What was compared
- Injected long-acting CJC-1295 versus placebo, using ascending study doses.
- What researchers found
- Researchers reported sustained increases in growth hormone and IGF-I, another hormone involved in growth signaling. No serious adverse reactions were reported in these short studies.
- What this leaves unanswered
- Hormone changes are laboratory outcomes. These studies do not establish improved injury healing, strength, athletic recovery, or long-term safety. Products sold under similar names or as blends cannot be assumed equivalent.
Research terms in everyday language ↗
Selected study summary based on the linked abstract; full-text appraisal, adverse-event detail, funding review, and a broader literature search are still pending.
Read findings in the context of the exact product or preparation, the people studied, and the outcome measured. These draft profiles are starting points, rather than complete systematic reviews.
Community research
Structured community reports can help identify questions worth studying. They are considered separately from controlled studies, with their limitations kept visible.
No community reports published yet.
This profile has no published community dataset. We do not infer a trend or a benefit from missing reports.
How community research will work ↗What we will document about community advice
- The advice
- What people recommend, with dated sources and the scope of the discussions examined.
- The reasoning
- Why contributors believe it helps, without treating that explanation as an established mechanism.
- The evidence
- What supports the claim, contradicts it, or has not been tested.
- The cautions
- Possible downsides, conflicting experiences, and questions for a clinician or pharmacist.
No recommendation or community consensus is established by this framework. Descriptions of how common advice is will need documented source coverage.
A closer look
- Classification
- Research profile
- Name variations
- Names you may see and important distinctions
- Source type
- Regulatory safety notice
- Reference jurisdiction
- United States
Interpret the source in the context of the preparation and route it discusses. A regulatory notice and a controlled clinical trial answer different questions.
This first design edition reserves space for study-by-study summaries, definitions, and technical references as each profile receives editorial review.
Go to the source
Study cards identify whether the summary uses an abstract, full text, or an agency assessment. Follow the linked sources for their original context.
Source reference · Checked 7 November 2026 · Opens in a new tab
For athletes: competition rules are a separate check ↗